Clinical Significance
This is the second phase 3 trial of SDX/d-MPH in children aged 6–12 years that adds to the safety and tolerability data from the short-term pivotal laboratory classroom study. The results of this 1-year study showed that SDX/d-MPH was safe, well tolerated, and had continued efficacy during the 1-year treatment period.